熱門資訊> 正文
Apellis Pharma公布了肾病治疗Pegcetacoplan的第二阶段数据
2024-05-25 01:12
- Pegcetacoplan, an investigational drug for post-transplant recurrence of C3 glomerulopathy, a condition that affects the kidneys, from Apellis Pharmaceuticals (NASDAQ:APLS) led to a rapid reduction in disease activity at week 12 in a phase 2 study.
- After one year of treatment, of the 11 patients treated with pegcetacoplan, seven (64%) patients showed a reduction in C3c staining by two or more orders of magnitude of intensity from baseline. Six (55%) showed zero C3c staining intensity. And seven patients (64%) showed zero inflammation.
- The phase 2 NOBLE study enrolled patients with post-transplant recurrence of C3 glomerulopathy or primary immune complex membranoproliferative glomerulonephritis.
More on Apellis Pharmaceuticals
- Apellis Pharmaceuticals Strives For Recovery Despite Syfovre Setbacks
- Apellis Pharmaceuticals, Inc. 2024 Q1 - Results - Earnings Call Presentation
- Apellis Pharmaceuticals, Inc. (APLS) Q1 2024 Earnings Call Transcript
- Apellis stock sell-off over Syfovre sales "overdone," says Citi
- Apellis Pharmaceuticals Q4 2023 Earnings Preview
推薦文章
風險及免責提示：以上內容僅代表作者的個人立場和觀點，不代表華盛的任何立場，華盛亦無法證實上述內容的真實性、準確性和原創性。投資者在做出任何投資決定前，應結合自身情況，考慮投資產品的風險。必要時，請諮詢專業投資顧問的意見。華盛不提供任何投資建議，對此亦不做任何承諾和保證。
